PolyPid Ltd. (PYPD) Reports Q3 Results; D-PLEX₁₀₀ FDA Decision Due Nov. 28

PolyPid reported third-quarter and nine-month 2026 financial results. Its D-PLEX₁₀₀ NDA is under FDA Priority Review with a PDUFA goal date of Nov. 28, 2026; the company also regained European commercialization rights and introduced PD01B.Material DetailsContext by AI AnalystThis update combines a…